Trinity provides commercial- ization strategy and services to pharmaceutical, biotech,
medical device, and diagnostic clients worldwide. Trinity is a leader in
creating innovative, evidence-based
solutions that drive business strategy and impact bottom lines. Dave
Fitzhenry, CEO & Managing Partner of Trinity Partners sat down
with Consulting to discuss the firm’s
Consulting: What were the main
factors that contributed to your firm’s
Fitzhenry: Throughout Trinity’s history, we have emphasized hiring the
best talent, focusing on development,
and setting our employees up for future
professional success. From an internal
perspective, we hold ourselves to exceptionally high standards in order to
support individuals' career growth, as
well as the continued growth of our
business. Trinity’s vast repository of
market based knowledge, innovative
processes and products combined with
the individual talent and expertise we
bring on an ongoing basis, ensure a
strong value proposition to our clients.
Consulting: How is this year shaping
up for your firm?
Fitzhenry: This year has been piv-
otal in Trinity’s history. We acquired
TGaS Advisors, the leading bench-
marking firm for commercial organi-
zations in the life sciences industry.
The acquisition marks another proof
point in Trinity Partners’ overarching
growth strategy of building a com-
plete solution set for the most critical
issues facing manufacturers today.
This acquisition builds upon previous
successes and momentum. Trinity
also expanded in the U.S. and global-
ly, opening an office in Gurgaon, In-
dia to complement our existing offic-
es in Waltham, New York, Princeton,
N.J. Philadelphia and San Francisco.
Consulting: How would you describe
your firm’s outlook for 2019?
Fitzhenry: Trinity’s having an exceptional 2018, exceeding even our most
aggressive organic growth targets all
while recapitalizing the company and
making our first acquisition. For 2019,
we couldn’t be more excited about our
prospects for growth. Successfully
launching and maximizing assets has
never been more challenging for our
clients, and Trinity is committed to
breaking new ground to help our clients overcome these challenges.
Consulting: What would you say are
your firm’s biggest challenges?
Fitzhenry: Our vision is to lead transformation in the life sciences industry,
guiding our clients with strategy and
insights that support the development
and delivery of life changing innovations to patients around the globe. Our
biggest challenges go beyond 2019
and the focal points will be managing
rapid growth while retaining a vibrant,
people-first culture of innovation,
which is at the core of Trinity’s focus.
After our recent acquisition of TGaS
Advisors, we will work to integrate
their strong talent and benchmarking
capabilities into our existing service
offerings all while continuing to innovate on our combined platforms to
develop best in class solutions.
Consulting: What does being named
one of Consulting’s Fastest Growing
Firms mean to your firm?
Fitzhenry: For us, being named one
of Consulting’s Fastest Growing
Firms for the fourth year in a row is incredibly exciting for us, and a tribute
to the thoughtfulness and dedication
of our teams. Growth is not easy, and
we are transparent with our employees about many of these challenges
because in the end, we're all in this
together. This recognition is a demonstration of the success of our model
and our commitment to culture.
*REVENUE GROWTH: 45% HQ:WALTHAM, MASS